PRESS RELEASE published on 01/24/2024 at 14:00, 1 year 10 months ago Pima Heart & Vascular Hosts Leading Cardiology Conference in Tucson This February Pima Heart & Vascular proudly announces its leadership role in hosting the CardioVascular Interventions Summit (CVIS) 2024. The summit, set for February 16-17 at the El Conquistador Tucson, Arizona, is a pinnacle of collaborative and innovative cardiovascular medicine, featuring a world-class faculty and live case sessions from major medical centers across the country. CVIS 2024 is designed to meet the educational needs of a diverse range of cardiovascular professionals, offering a hybrid conference model for both in-person and virtual attendees. Industry partners have unique opportunities to engage directly with thought leaders, practitioners, and decision-makers in cardiovascular medicine. For more information and to register, please visit CVISummit.com. CardioVascular Interventions Summit 2024 Pima Heart & Vascular Cardiovascular Medicine CVIS 2024 Cardiac Care
Published on 12/05/2025 at 02:35, 4 hours 2 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 37 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 32 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 37 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 7 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 46 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 12 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 22 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 26 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 22 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL